{"id":"standard-dose-oxcarbazepine","safety":{"commonSideEffects":[{"rate":"25–50%","effect":"Dizziness"},{"rate":"20–30%","effect":"Somnolence"},{"rate":"15–25%","effect":"Diplopia"},{"rate":"10–15%","effect":"Ataxia"},{"rate":"10–15%","effect":"Nausea"},{"rate":"2–3%","effect":"Hyponatremia"},{"rate":"<1%","effect":"Rash (including Stevens-Johnson syndrome)"}]},"_chembl":{"chemblId":"CHEMBL1068","moleculeType":"Small molecule","molecularWeight":"252.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxcarbazepine is a prodrug that is rapidly metabolized to its active metabolite, 10-monohydroxy derivative (MHD). This metabolite binds to inactivated sodium channels, preventing their reopening and thereby reducing the propagation of action potentials. Additionally, it may enhance potassium conductance and modulate calcium channels, contributing to its anticonvulsant and mood-stabilizing effects.","oneSentence":"Oxcarbazepine blocks voltage-gated sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing hyperexcited neural tissue.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:11.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (monotherapy and adjunctive therapy)"},{"name":"Generalized tonic-clonic seizures (adjunctive therapy)"},{"name":"Bipolar disorder (off-label use)"}]},"trialDetails":[{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT02078089","phase":"PHASE1","title":"Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain","status":"TERMINATED","sponsor":"Costantine Albany","startDate":"2014-03-06","conditions":"Cancer","enrollment":1},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard oxcarbazepine"],"phase":"marketed","status":"active","brandName":"Standard dose oxcarbazepine","genericName":"Standard dose oxcarbazepine","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxcarbazepine blocks voltage-gated sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing hyperexcited neural tissue. Used for Partial-onset seizures (monotherapy and adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy), Bipolar disorder (off-label use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}